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ABSTRACT
Introduction Managing chronic musculoskeletal problems 
usually focuses on pain control using medications, but 
outcomes are often unsatisfactory and sometimes harmful. 
Information on a patient’s health- related quality of life 
(HRQOL) may trigger a doctor to tailor management 
improving quality of life. The aim of this trial is to find out 
whether routine measurement and reporting of a patient’s 
EuroQoL 5- Dimension 5- Level (EQ- 5D- 5L) HRQOL data 
using an electronic platform can improve HRQOL and pain 
in patients with chronic knee or back problems in primary 
care. We will also assess the acceptability of routine 
electronic measurements and reporting of the EQ- 5D- 5L in 
primary care settings.
Methods This is a multicentre, prospective, cluster 
randomised controlled trial set in six public primary care 
clinics in Hong Kong. At the intervention clinics, subjects 
will complete an electronic EQ- 5D- 5L form at recruitment 
and at each clinic follow- up over 12 months. A report of 
the patient’s longitudinal EQ- 5D- 5L data will be provided 
to the doctor. Subjects in the control clinics will receive 
care as usual. All subjects will complete the Western 
Ontario and McMaster Universities Osteoarthritis Index 
(WOMAC), a 10- point Pain Rating Scale and a structured 
questionnaire to collect sociodemographic information and 
data on morbidity and service utilisation at recruitment 
at baseline, 3, 6 and 12 months. Primary outcome is the 
change in WOMAC total score. Secondary outcomes are 
change in pain, other patient- reported outcome scores and 
doctor- rated severity of disease. Group differences in the 
changes in WOMAC and other outcome scores over time 
will be analysed using generalised estimating equation 
model with an intention- to- treat principle.
Ethics and dissemination Ethics approval has been 
obtained from The University of Hong Kong/Hospital 
Authority Hong Kong West Cluster (IRB reference number: 
UW 18-270). The results of the trial will be submitted for 
publication in a peer- reviewed journal.
Trial registration number NCT03609762.
INTRODUCTION
With ageing of the population and physical 
inactivity in today’s industrialised society, muscu-
loskeletal (MS) problems have become an 
important disease burden, affecting hundreds 
of millions of people worldwide.1 MS problems 
account for 7% of all the diagnoses presenting 
to primary care in Hong Kong.2 Although the 
spectrum of MS problems is broad, ranging 
from the common muscle strain, tendinitis 
and degenerative conditions to the more 
serious inflammatory joint diseases, they share 
Strengths and limitations of this study
 ► This is the first study to evaluate the impact of rou-
tine measurements of health- related quality of life 
(HRQOL) in normal clinical practice in a Chinese 
population.
 ► It is an effectiveness- implementation hybrid trial 
that aims to promote more effective and patient- 
centred care of people with chronic musculoskeletal 
problems.
 ► The study aims to overcome implementation bar-
riers by using modern information technology to 
collect and generate a patient- filled report on the 
relevant HRQOL data with reference to the general 
population norm at the point of care in real- world 
primary care clinics.
 ► If found to be effective, evidence from this study can 
support the integration of routine HRQOL data col-
lection into electronic medical record systems.
 ► As the instruments will be collected using elec-
tronic tablets, a certain level of computer literacy is 
required, and the study may not be able to include 
participants who are unable to perform such tasks 
which may introduce selection bias associated with 
age or educational status.
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the common characteristics of causing pain and disability. 
Chronic MS problems are the most common cause of severe 
chronic pain impairing mental and physical well- being.3 
The Global Burden of Disease Study 2013 showed that from 
2005 to 2013, the major contributor to the global increase of 
disability- adjusted life years was MS problems.3 Four of the 
top 10 causes of disability in China are MS problems, namely 
low back pain, neck pain, osteoarthritis and other MS prob-
lems.4 MS problems also significantly affect the psychosocial 
health of the patients’ families and caregivers. Current clin-
ical management of chronic MS problems focuses predomi-
nantly on pain control with medications, but the outcomes 
are often unsatisfactory. There are increasing concerns 
regarding serious side effects from the use of non- steroidal 
anti- inflammatory drugs, and the risk of death and depen-
dency from opioids in the treatment of chronic pain.5 More 
effective interventions are needed to reduce the suffering, 
disability and service burden arising from MS problems.
The goal of medical care is to improve or restore health 
and the patient’s perspective needs to be taken into 
account when assessing the outcomes of care. Patient- 
reported outcomes (PRO) are defined as ‘any report 
of the status of a patient’s health condition that comes 
directly from the patient, without interpretation of the 
patient’s response by a clinician or anyone else’.6 Pain is 
a commonly used PRO in clinical practice. Health- related 
quality of life (HRQOL) is becoming a popular PRO 
measure in clinical trials. HRQOL is a multidimensional 
concept that measures a person’s subjective perceived 
effect on how health has affected his/her ability to live 
a fulfilling life, both physically and mentally.7 A variety of 
HRQOL instruments are available for different purposes, 
which can be generic or disease specific.7 There is a large 
body of evidence on the psychometrics and clinimetrics of 
HRQOL measures in assessing the severity of symptoms,8 
monitoring general health and well- being,9 promoting 
patient–clinician communication,10 evaluating treat-
ment/intervention outcomes11–13 and informing clinical 
decision- making.11 12 14 15
Up until now, HRQOL has rarely been measured in 
normal clinical practice because it requires a paradigm 
shift from objective to subjective outcome measurements, 
and strategies to overcome the implementation barriers 
of time, workload, cost and patient burden.12
The choice of instrument is critical for successful imple-
mentation when measuring HRQOL in normal clinical 
practice. It should be valid, reliable, applicable to most 
if not all patients, short and easy to use, and meaningful. 
The EuroQol-5 Dimension (EQ- 5D) questionnaire 
developed by the EuroQol Group is a generic HRQOL 
measure that satisfies all these criteria.16 It consists of a 
descriptive system of five HRQOL dimensions (mobility, 
self- care, usual activities, pain/discomfort and anxiety/
depression) and a 200 mm visual analogue scale (VAS) 
for global health rating. It can be completed within a 
few minutes either by self- completion or by interview 
administration. The original EQ- 5D has three response 
options to each item (EQ- 5D- 3L), but was modified to 
the EuroQoL 5- Dimension 5- Level (EQ- 5D- 5L) with five 
response options to each item to improve responsiveness 
and sensitivity.16 The EQ- 5D- 5L defines a combination of 
3125 health states.16 Each health state can be converted to 
a composite utility (preference) score from 0 (death) to 
1 (perfect health), with a scoring algorithm derived from 
population- based valuation. The EQ- 5D has been adapted 
in many countries with population- specific scoring algo-
rithms available in the USA, Canada, Europe and China. 
A Chinese (Hong Kong) version of the EQ- 5D- 5L has 
been validated and the Hong Kong population- specific 
EQ- 5D- 5L scoring algorithm has been developed from 
a population- based valuation study.17 18 The EQ- VAS is a 
200 mm vertical scale ranging from 0 to 100, with 0 corre-
sponding to ‘the worst imaginable health’ and 100 indi-
cating ‘the best imaginable health’, and the rating scale 
scores are an easy- to- interpret composite indicator that 
can be used to monitor the change in HRQOL over time. 
The EQ- 5D- 5L has been shown to be valid, reliable and 
sensitive in patients with MS problems internationally 
and in Hong Kong.19
Aims and hypothesis
The aim of this study is to find out whether the imple-
mentation of routine measurement and reporting of 
the patient’s EQ- 5D- 5L HRQOL data with an electronic 
platform can improve HRQOL and pain in patients with 
chronic knee or back problems in primary care. We will 
also assess the acceptability of the implementation of 
routine electronic measurement and reporting of the 
EQ- 5D- 5L HRQOL data in real- world primary care. We 
hypothesise that the real- time report on longitudinal 
HRQOL data will facilitate a more patient- centred care 
with optimisation of the use of drugs, counselling, rehabili-
tation service, aids and/or surgery to address the patient’s 
physical, social and psychological needs. Furthermore, 
the EQ- 5D report can make the patient more aware of 
his/her condition, and will become more motivated and 




This study is a single- blind cluster randomised controlled 
trial (RCT) to evaluate the effectiveness of measuring 
and reporting HRQOL in routine clinical practice in 
improving the outcomes of patients with chronic knee 
and/or back problems. Randomisation will be performed 
at the clinic level. Recruited subjects from the control 
and intervention clinics will be followed up at 3, 6 and 12 
months after enrolment into the trial (figure 1).
Subjects
Recruitment
We will recruit subjects from six primary care clinics, three 
of which will be randomised as the intervention clinics 
and three as the control clinics. All adults attending the 
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study clinics for symptomatic chronic knee and/or back 
pain will be assessed by the attending doctors and invited 
to join the study if they satisfy the following inclusion 
criteria and do not meet any of the exclusion criteria.
The inclusion criteria are:
A. Adults aged 18 years or above.
B. Has a doctor- diagnosed symptomatic knee and/or 
back pain problem that is expected to last for 1 month 
or more.
C. Scheduled for at least one follow- up visit in the clinic 
within 12 months.
D. Has given written consent to participate in this study.
The exclusion criteria are:
A. Life expectancy less than 12 months (judged by the 
doctor).
B. Has cancer. (Patients with current cancers undergoing 
active or palliative treatment will be excluded since 
they may have impairment of quality of life from can-
cer and opioids or other pain relief treatments, which 
would make an independent evaluation of the out-
comes related to the chronic (non- malignant) knee or 
back pain impossible.)
C. Too ill (both physically or cognitively) to complete a 
questionnaire.
D. Unable to communicate in Chinese.
E. Does not give consent to participate in the study.
The doctor will complete the clinician- reported base-
line clinical case report form (CRF)) for each eligible 
patient at the end of their consultation. Each subject 
will sign a written consent form (online supplemental 
appendix 1) and then complete a structured question-
naire containing items on sociodemographics, service 
utilisation, pain rating and quality of life.Subjects receu-
ited from the intervention clinics will also complete the 
electronic EQ- 5D- 5L on a computer tablet in the clinic 
after the doctor’s consultation. The name and telephone 
number of each subject will be collected for the follow- up 
telephone interviews.
To ensure the feasibility and acceptability of the measure-
ment and reporting of the EQ- 5D- 5L before the doctor 
consultation in busy outpatient clinics, a pilot study was 
undertaken in July to December 2018 in two outpatient 
clinics. All 151 subjects recruited were able to complete the 
electronic EQ- 5D- 5L in a mean time of 2 min; 69% of the 
patients perceived the electronic EQ- 5D- 5L survey as both 
easy to use and understand and 95% thought the assess-
ment was useful. Among the EQ- 5D reports provided to the 
doctors involved in the pilot, 88% of the EQ- 5D- 5L reports 
were rated as easy to understand and 80% of the EQ- 5D- 5L 
results were rated as being useful by the doctors. The elec-
tronic EQ- 5D- 5L platform operated smoothly with a note-
book computer or iPad connected to the clinic public Wi- Fi 
and the report was able to be generated within seconds.
Randomisation
A statistician not involved in subject recruitment or data 
collection will carry out the randomisation of the clinics 
into the intervention group (three clinics) and control 
group (three clinics). The allocation will be blinded to 
the interviewers (assessors) who administer the telephone 
surveys on the outcomes, and the research team member 
who will carry out the data analysis.
Figure 1 Study flow diagram. CRF, case report form; EQ-
5D- 5L, EuroQoL 5- Dimension 5- Level; GRS, Global Rating 
Scale; PEI, Patient Enablement Instrument; PRO, patient- 
reported outcome; SF- 6D, Short- Form Six- Dimension; 
WOMAC, Western Ontario and McMaster Universities 
Osteoarthritis Index.
Figure 2 Example of the EuroQoL 5- Dimension 5- Level (EQ- 5D- 5L) utility score and rating scale score. HK, Hong Kong; VAS, 
visual analogue scale.
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Intervention group (EQ-5D-5L HRQOL results will be available to 
the attending doctor)
All subjects attending the intervention clinics will complete 
the electronic EQ- 5D- 5L before seeing the doctor during 
each follow- up visit for the MS problem, a printout of the 
longitudinal EQ- 5D- 5L data (table 1) since recruitment 
will be given to the patients to show to the attending 
doctors during the consultation. The doctors will provide 
the management based on the usual clinical information 
and the additional EQ- 5D- 5L HRQOL results (figure 2). 
The doctor will complete the clinician- reported follow- up 
clinical data form (CRF) of each eligible patient at the 
end of the consultation.
Control group (usual care, EQ-5D-5L HRQOL results will not be 
available to the attending doctor)
Subjects attending the control clinics will not need to 
complete the electronic EQ- 5D- 5L before seeing the 
doctor during their follow- up visits. The doctor will 
manage the patient as usual, based on the usual clinical 
information. The doctor will complete the clinician- 
reported follow- up clinical data form (CRF) for each 
subject at the end of the consultation.
Training and consent of clinicians
The investigators (CL, JPYC, CKHW) will provide a 
training session on the interpretation of the EQ- 5D- 5L 
HRQOL profile and VAS scores to all doctors of the inter-
vention clinics. Each participating doctor will complete a 
consent form (online supplemental appendix 2) to take 
part in the study.
Outcome measures
Primary outcome
The primary outcome is the change in HRQOL measured 
by the Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC) total score.
Secondary outcomes
1. Change in pain score as measured by the 10- point Pain 
Scale.
2. Change in PROs: Short- Form Six- Dimension (SF- 6D) 
utility score, global health measured by the Global Rat-
ing Scale (GRS), patient enablement measured by the 
Patient Enablement Instrument (PEI) score.
3. Change in clinician- reported disease severity and 
progression.
Exploratory outcomes
1. Health service utilisation rates.
2. Drug and other treatment utilisation rates.
3. Patient acceptability of routine measurement of 
HRQOL by the electronic EQ- 5D- 5L.
Confounders
Clinical settings, sociodemographics, MS diagnosis, dura-
tion and severity, treatment and comorbidity.
Sample size calculation
The sample size calculation was based on the primary 
outcome of a difference in WOMAC total score between 
the intervention and control groups. A previous RCT 
study evaluating a rehabilitation programme integrating 
exercise, self- management and active coping strategies 
for patients with chronic knee pain showed that the 
average change in WOMAC total score at 6 months after 
baseline for the intervention and control groups was −3.4 
(mean: 35; SD: 16 at 6 months) and −8 (mean: 30.4; SD: 
17 at 6 months), respectively,20 indicating an effect size of 
0.3. Using this, a minimum of 380 (190 in each group) 
patients are needed to achieve 80% power at 5% signifi-
cant level, by two- sample t- test. There were no studies that 
provided an intracluster correlation (ICC) coefficient for 
WOMAC scores, but a review showed the ICC coefficient 
of pain outcome was 0.0321; to adjust for the clustering 
effect from six clinics, a larger sample size of 1098 (549 
patients per group, and 183 subjects per clinic) will be 
required. We plan to recruit 1374 (687 in each group) 
subjects to allow for a 20% attrition rate.
Study instruments
Chinese (Hong Kong) EQ- 5D- 5L and the acceptability of 
routine completion of the electronic EQ- 5D- 5L:
1. The electronic Chinese EQ- 5D- 5L comprises a de-
scriptive system of five questions on five HRQOL di-
mensions (mobility, self- care, usual activities, pain/
discomfort and anxiety/depression) and a 100 mm 
(adapted from 200mm to fit the Tablet screen) VAS on 
global health from 0 corresponding to ‘the worst imag-
inable health’ to 100 indicating ‘the best imaginable 
health’. Each question has five response options (1=no 
problems, 2=slight problems, 3=moderate problems, 
4=severe problems, 5=extreme problems). The re-
sponses to the five questions give an HRQOL profile.16
2. The acceptability of routine completion of the elec-
tronic EQ- 5D- 5L will be evaluated by the perceived 
ease of use and perceived usefulness scales based on 
Table 1 Example of the EuroQoL 5- Dimension 5- Level (EQ- 





median Time 1 Time 2 Time 3
Mobility 1 1 2 1
Self- care 1 1 1 1
Usual activities 1 1 1 1
Pain/discomfort 1 2 2 3
Anxiety/depression 2 2 2 2
Present the level of each domain at each time point.
EQ- 5D- 5L level: 1=no problems, 2=slight problems, 3=moderate 
problems, 4=severe problems, 5=extreme problems.
EQ- 5D- 5L, EuroQoL 5- Dimension 5- Level; HK, Hong Kong.
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the technology acceptability model, which was trans-
lated and validated on a local Chinese population.22 
Their Cronbach’s alpha was 0.90 and 0.89, respective-
ly. They had good convergent validity with significant 
correlation of 0.69.
PROs on:
1. Chinese Western Ontario and McMaster Universities 
Osteoarthritis Index (WOMAC): the WOMAC is a 
widely used condition- specific HRQOL measure to 
assess pain, stiffness and physical function (PF) of pa-
tients with MS problems. It has been applied to pa-
tients with hip and/or knee osteoarthritis, low back 
pain, rheumatoid arthritis and fibromyalgia.23 It con-
sists of 24 items on three domains: pain (5 items), 
stiffness (2 items) and PF (17 items). Each question 
is rated on a 5- point Likert scale from 0 to 4, with low-
er scores indicating lower levels of symptoms or im-
pairment. The item scores in each domain subscale 
are summated to a domain score. The total WOMAC 
score is calculated by summating the three domain 
scores. A Chinese version of the WOMAC is available 
and has been shown to be valid, reliable and sensitive 
in Chinese patients.24
2. Ten- point Pain Scale: the patient will be asked to rate 
their pain that best represents the intensity of their 
pain using a scale from 0 to 10, where 0 indicates no 
pain and 10 indicates the worst pain.
3. Chinese Short- Form Six- Dimension (SF- 6D): the SF- 6D 
is a preference- based measure of health, derived from 
the 36- Item Short Form Health Survey, that generates 
a utility score. It has six items measuring six HRQOL 
dimensions of physical functioning, role limitation, so-
cial functioning, bodily pain, mental health and vitali-
ty. The SF- 6D responses have a combination of 18 000 
health states. Each health state can be converted to a 
composite preference (utility) score from 0 indicating 
death to 1 indicating perfect health. The Chinese SF- 
6D was validated in the Chinese population in Hong 
Kong,25 and a Hong Kong population- based scoring al-
gorithm has been established. The mean SF- 6D utility 
score of the Hong Kong Chinese population is 0.78.25
4. Chinese Patient Enablement Index (PEI): the PEI is a 
six- item questionnaire that measures the patient’s per-
ceived change in coping with illness and self- care. Each 
item is rated on a 3- point (0, 1 and 2) scale. The sum 
of the item scores gives the final PEI score, with high-
er scores indicating better enablement. The Chinese 
version was shown to be a valid, reliable and sensitive 
outcome measure among Chinese patients in Hong 
Kong.26
5. Global Rating Scale (GRS): the GRS on change in 
health will be used to assess the patient’s self- perception 
of any change in the overall health condition on a 
7- point scale: −3 (much worse), −2 (worse), −1 (a little 
worse), 0 (no change), 1 (a little better), 2 (better), 3 
(much better).27
A structured questionnaire (online supplemental 
appendix 3—baseline and follow- up) on
1. Sociodemographic characteristics including age, sex, 
education background, marital status, occupation, 
monthly household income, smoking and drinking 
status.
2. Comorbidities: the presence of doctor- diagnosed 
chronic diseases including hypertension, diabetes, 
stroke, heart disease, pulmonary diseases including 
asthma and chronic obstructive pulmonary disease, 
mental illness, renal disease, osteoporosis, cancer and 
others.
3. Health service utilisation: monthly frequency of out-
patient consultations with Western/Chinese medicine 
practitioners, allied health service visits, accident and 
emergency department attendance and admissions to 
hospitals.
4. Days of sick leave in the past 1 month.
5. Medication use in the past 1 month.
Clinician- reported clinical case report form (CRF) 
(online supplemental appendix 4—baseline and 
follow- up) on:
1. Disease diagnosis and duration: the diagnosis and du-
ration of the chief MS problem will be reported by the 
attending doctor.
2. Global rating on disease severity: the attending doc-
tor will rate the patient’s disease severity on a 5- point 
Likert scale: 1=no problem, 2=mild, 3=moderate, 4=se-
vere, 5=very severe.
3. Global rating on disease progression: in each follow- 
up clinic consultation, the attending doctor will rate 
the patient’s disease progression on a 7- point scale: −3 
(much worse), −2 (worse), −1 (a little worse), 0 (no 
change), 1 (a little better), 2 (better), 3 (much better).
4. Disease management: the management modalities in-
cluding investigations, drugs (type and dosage), refer-
ral to allied health service (types and frequency) and 
surgery (type and year of the surgery) will be extracted 
from the medical record.
5. Perceived usefulness of the EQ- 5D- 5L data in enhanc-
ing patient management.
Data collection
A computer program will be developed to administer the 
electronic version of the Chinese (Hong Kong) EQ- 5D- 5L 
on a computer tablet, to calculate the utility score and to 
generate a report on the longitudinal EQ- 5D- 5L profile 
scores, preference scores and VAS scores in a printable 
form (table 1 and figure 2).
All subjects from the intervention clinics will complete 
the electronic Chinese (Hong Kong) EQ- 5D- 5L at recruit-
ment and during every follow- up visit at the clinic before 
the doctor consultation over the next 12 months.
To control for potential confusing variables and errors, 
a trained research assistant will assist the subjects in the 
completion of the electronic EQ- 5D- 5L. All other patient 
data will be collected by interviewers who will be trained 
by the project coordinator to ensure all questions are 
asked in a standardised manner. We will conduct briefing 
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meetings with the doctors in charge of all participating 
clinics and send a written briefing of the study and a 
guide on the interpretation of the EQ- 5D- 5L report to 
each participating doctor.
The doctor will complete the CRF (online supplemental 
appendix 4) for each study subject after the consultation 
at recruitment and during every follow- up consultation 
over the next 12 months for subjects from both the inter-
vention and control clinics.
A survey on sociodemographic, comorbidity, PRO and 
health service utilisation will be administered to each 
subject within 2 weeks from recruitment (baseline), and 
the survey on PRO and health service utilisation will be 
repeated by telephone at 3, 6 and 12 months (blinded 
to group allocation) after the baseline survey. The tele-
phone survey will be carried out by the HKU Social 
Science Research Centre. Data collection at baseline and 
follow- up for intervention and control groups is shown in 
table 2.
Data processing and analysis
Data will be analysed by intention to treat, in which all 
subjects who are randomised and have completed at least 
one repeat outcome measurement will be included in 
the analysis. Multiple imputations will be used to substi-
tute missing data. Complete case analysis will also be 
conducted to confirm the results.
The within- group changes in WOMAC, pain and SF- 6D 
scores will be compared by paired t- test, or Wilcoxon 
signed- rank test if the outcome data are not normally 
distributed. Between- group difference of changes in 
WOMAC, pain and SF- 6D scores, and between- group 
difference in GRS and PEI scores at the end of 12 months 
will be compared by two- sample t- test, or Mann- Whitney 
U test if the outcome data are not normally distributed.
The differences between groups in outcomes, including 
WOMAC, pain, SF- 6D, GRS and PEI, will be assessed by 
the generalised estimating equations (GEE).28 Specifi-
cally, we shall use the identity link to regression on group, 
baseline value and time, and allow extra- covariance of 
repeated from the same subject and different subjects 
from the same cluster by an unstructured working covari-
ance matrix. Between- group differences in clinician- rated 
disease severity rates of medication use, service utilisa-
tion and sick leave will be similarly assessed by GEE but 
with a Poisson link to cater the different measurement 
scale of the outcomes. The acceptability of measure-
ment of routine HRQOL measurement by the electronic 
EQ- 5D- 5L will be summarised by descriptive statistics on 
patient and doctor evaluation.
The STATA software V.13 (StataCorp, Texas) will be 
used for the data analysis. A 5% level of significance will 
be used in all significance tests.
Data monitoring
An external data monitoring committee was not deemed 
to be necessary for this trial. Data will be monitored by 
the research team which includes clinicians, statisticians 
and information technology experts. This study is consid-
ered to be a low- risk trial where both the intervention and 
control groups will receive their usual medical care. Rules 
for early stopping have not been implemented as the 
clinicians involved in this study are not blinded to inter-
vention allocation.
Table 2 Data collection at baseline and follow- up for 
intervention and control groups
Baseline Follow- up
  Intervention Control Intervention Control
1. Patient- reported outcomes
  EQ- 5D- 5L × × × ×
  WOMAC × × × ×
  SF- 6D × × × ×
  PEI     × ×
  GRS     × ×
  Patient acceptability 
questionnaire
× ×     
2. Sociodemographic status and lifestyle
  Age × ×     
  Sex × ×     
  Education 
background
× ×     
  Occupation × ×     
  Monthly household 
income
× ×     
  Smoking × ×     
  Drinking × ×     
3. Burden of illness
  Medical service 
utilisation
× × × ×
  Sick leave × × × ×
  Use of medication × × × ×
4. Clinician- reported outcomes
  Global rating on 
disease severity
× × × ×
  Global rating on 
disease progression
    × ×
  Doctor acceptability 
questionnaire
    × ×
5. Clinical data
  Disease diagnosis 
and duration
× ×     
  Drug treatment × × × ×
  Comorbidities × × × ×
  Investigations/ 
referrals
× × × ×
EQ- 5D- 5L, EuroQoL 5- Dimension 5- Level; GRS, Global Rating 
Scale; PEI, Patient Enablement Instrument; SF- 6D, Short- Form Six- 
Dimension; WOMAC, Western Ontario and McMaster Universities 
Osteoarthritis Index.
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Collection and assessment of reported adverse events 
and other unintended effects of the trial interventions 
or trial conduct will be performed on a continuous basis 
as such events arise. Queries identified will be resolved 
promptly by the research team. All unintended effects 
and adverse events will be reported every 6 months to 
the Institutional Review Board (IRB) of the University 
of Hong Kong and Queen Mary Hospital. Interim anal-
yses will be reported to the IRB and funding body every 
6 months. The principal author (CL) will be responsible 
for overseeing the interim analyses and any decisions to 
stop the trial.
Patient and public involvement
This research is planned to be done without patient 
involvement. Patients will not be invited to comment 
on the study design and will not be consulted to 
develop patient- relevant outcomes or interpret the 
results. Patients will not be invited to contribute to the 
writing or editing of the future manuscript for read-
ability or accuracy.
DISCUSSION
Routine measurement of HRQOL in normal clinical 
practice has been used in selected patient populations, 
mostly in oncology29 and specific surgical settings in 
the UK and Sweden.14 In the UK, as a government 
initiative to compare service providers’ performance, 
HRQOL has been routinely measured by the EQ- 5D 
before and after the National Health Service funded 
elective hip or knee replacement, varicose vein and 
inguinal hernia surgeries since 2009. This changes the 
paradigm of evaluation of effectiveness of care from 
the clinician to the patient’s perspective in order to 
improve accountability.29 It also enables patients to 
make an informed choice on service providers.29 In 
Sweden, the Swedish Hip Arthroplasty Register has 
recorded the EQ- 5D utility score and a VAS pain 
score of each patient since 2002, and demonstrated 
that the overall PRO of total hip replacement surgery 
is satisfactory, leading to a mean increase of 0.36 in 
EQ- 5D utility score.14 Data on routine measurement 
of HRQOL by the EQ- 5D or other measures in busy 
outpatient settings are currently lacking, and we 
could not find any study on routine measurement 
of HRQOL in normal clinical practice in Chinese 
populations.
In preparation for this study, we have developed an 
electronic platform for the administration, scoring 
and reporting of EQ- 5D- 5L data in normal outpa-
tient clinics, which can make the results available to 
the attending doctors in real time (a mock example is 
shown in figure 3). If found to be beneficial, routine 
measurement of HRQOL by an electronic EQ- 5D- 5L 
platform may be applied to other outpatient clinics 
to help improve the care of MS problems and other 
conditions, and to facilitate more effective and 
patient- centred care.
DATA MANAGEMENT AND OVERSIGHT
Members of the research team from the University of 
Hong Kong will take responsibility for the conduct 
of research staff and study participants to ensure 
protocol compliance, proper study management and 
timely completion of study procedures. The Consoli-
dated Standards of Reporting Trials table with the RCT 
plan is available at online supplemental appendix 5.
PROTOCOL AND REGISTRATION
The trial is registered with the US Clinical Trial Registra-
tion at  ClinicalTrials. gov; protocol ID HKUCTR-2418.
DATA STORAGE SECURITY AND PATIENT CONFIDENTIALITY
Personal identifiable information will be deidentified 
and replaced with research identification codes. Data 
sets will have all personal identifiers removed so that 
participant identities cannot be determined in case 
of data security breaches. Cover and consent sheets 
containing identifiable information will be stored 
separately from any completed survey instruments and 
access to master code lists will be limited to the inves-
tigation team only. Individual files containing elec-
tronic data will be password protected and encrypted 
and stored on institutional network drives with fire-
walls and security measures in place. Consent forms 
and other hard copy records will be stored securely 
Figure 3 Example of an electronic platform for measuring 
and scoring EuroQol-5 Dimension (EQ- 5D).
 on M









pen: first published as 10.1136/bm






8 Lam C, et al. BMJ Open 2020;10:e040373. doi:10.1136/bmjopen-2020-040373
Open access 
in a locked cabinet in a secure location separate 
from where the research data are kept. All research 
staff will be trained in the IRB- approved methods for 
managing and storing research data.
ETHICS AND DISSEMINATION
Ethics approval hasbeen obtained from Institutional 
Review Board of The University of Hong Kong/Hong 
Kong/ Hospital Authority Hong Kong West Cluster 
(IRB Reference Number: UW18-270) who have 
reviewed and approved the study procedures, ethics, 
subjectinformation and consent, and subject safety. 
The results of the trial will be submitted for publica-
tion in a peer- reviewed journal.
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Research conducted by 
Department of Family Medicine and Primary Care, HKU  
Information and Consent Form  
 
Effectiveness of Routine Measurement of Health-Related Quality of Life in Improving 
the Outcomes of Patients with Musculoskeletal Problems – A Randomized 
Controlled Trial 
 
Thank you for reading this information and agreeing to consider taking part in this study. Please read 
this form, and if you have understood the purpose and procedure of the study and kindly agree to take 
part, please sign and date at the end of this Consent Form. 
 
Study Information 
The aim of this research is to determine the effectiveness of routine measurement of health- related 
quality of life (HRQOL) in improving the clinical outcomes of patients with chronic musculoskeletal 
problems in primary care. You will be invited to answer a structured questionnaire administered by a 
research assistant at the time of recruitment. During the 12 months of follow-up, each time when you 
visit the clinic, you will be invited to complete a short electronic questionnaire on HRQOL. We will also 
contact you through telephone to collect follow-up information 3, 6 and 12 months later. Each 
telephone survey will last for about 10 minutes. 
Your doctor-in-charge will receive the reports of your HRQOL measured on the day of every follow up 
consultation during the study period, and he/she will manage your musculoskeletal problem taking into 
consideration of your clinical and HRQOL conditions. Your doctor-in-charge will also be asked to rate provide 
information about your disease and management.  
All the data collected from you will be kept confidential and no individual identity information will be 
disclosed in any reports, data record forms or publications. 
 
You can withdraw from the study anytime you want without infringement on any of your rights to treatment 
in this clinic or other services provided by the Hospital Authority. 
 
For further information please contact: 
Prof. Cindy Lam / Dr. Carlos Wong, Department of  amily Medicine and Primary Care,The University of 
Hong Kong, 3/F., Ap Lei Chau Clinic, 161 Main Street, Ap Lei Chau, Hong Kong  
Telephone: 25185657; Fax: 2814 7475 
 
Declaration on Protection of Personal Data 
Under the laws of the Hong Kong Special Administrative Region and, in particular, the Personal Data 
(Privacy) Ordinance, Cap 486, you enjoy or may enjoy rights for the protection of the confidentiality of your 
personal data, such as those regarding the collection, custody, retention, management, control, use (including 
analysis or comparison), transfer in or out of Hong Kong, non-disclosure, erasure and/or in any way dealing with 
or disposing of any of your personal data in or for this study. 
By signing and dating this Consent Form, you agree to allow the collection, custody, retention, 
management, control, and use your personal data in this study in ways described in the Information Leaflet. For 
any query, you should consult the Privacy Commissioner for Privacy Data or his office ( Tel No. 2827 2827) as 
to the proper monitoring or supervision of your personal data protection so that your full awareness and 
understanding of the significance of compliance with the law governing privacy data is assured. 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
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Consent Form  
 
The following statements are to check that you understand and consent to the procedures 
involved in taking part in this research. 
 
 
1. I confirm that I have read and understood (or had someone read and explained) the 
information for the above study and have been given a copy to keep. I have had the 
opportunity to ask questions about the project and I understand why the research is being 
done and any risks involved. 
2. I understand that my participation is voluntary. 
3. I agree to take part in the study. 
4. I agree to complete the electronic EQ-5D health-related of life questionnaire (5 questions) 
every time I visit the clinic. 
5. I agree to finish a baseline questionnaire through face-to-face interview by an interviewer 
at the clinic. 
6. I understand that I need to complete a telephone survey at 3, 6 and 12 months after the 
baseline questionnaire to monitor my progress, which will take about 10 minutes. 
7. I understand that my doctor-in-charge may get my HRQOL report, and provide information 
on my diagnosis and treatment at every follow up consultations during the 12 months of the 
study. 
8.  I understand that all information that I provide to the research team will be kept confidential 
and only the investigators and their research team will have access to it. 
9. I understand how the data will be collected, that giving data for this research is voluntary 
and that I am free to withdraw the permission to use my data at any time, without giving 
reason and without my medical treatment or legal rights being affected. 
10. I understand that I am free to withdraw from the study at any time, without giving reason 
and without my medical treatment or legal rights being affected in any way. 
11. I understand the investigators have the right to exclude me from the study in the event of 
inter-current illness, adverse event, protocol violations, or other reasons. 
 
 




……………………………… ……………………………….. …..……………… 





……………………………… ……………………………….. …..……………… 
Name of Investigator in BLOCK letters      Signature Date 
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Information and Consent Form  
 
Effectiveness of Routine Measurement of Health-Related Quality of Life in Improving the 
Outcomes of Patients with Musculoskeletal Problems – A Randomized Controlled Trial 
 
 
Thank you for reading this information and agreeing to consider taking part in this study. Please read this 
form, and if you have understood the purpose and procedure of the study and kindly agree to take part, 





The aim of this research is to aim to determine the effectiveness of routine measurement of health-related 
quality of life (HRQOL) in improving the clinical outcomes of patients with chronic musculoskeletal 
problems in primary care. You will be invited to answer a structured questionnaire administered by a 
research assistant at the time of recruitment. Your doctor-in-charge will manage you as usual and then 
complete a form to provide information on your disease and management at every follow up during the 
12-month study period. We will also contact you through telephone to collect follow-up information at 3, 
6 and 12 months after the baseline questionnaire survey. Each telephone survey will last about 10 
minutes. 
 
All the data collected from you will be kept confidential and no individual identity information will be 
disclosed in any reports, data record forms or publications. 
 
You can withdraw from the study anytime you want without infringement on any of your rights to treatment 
in this clinic or other services provided by the Hospital Authority. 
 
 
For further information please contact: 
Prof. Cindy Lam / Dr. Carlos Wong, Department of  amily Medicine and Primary Care,The University of 
Hong Kong, 3/F., Ap Lei Chau Clinic, 161 Main Street, Ap Lei Chau, Hong Kong  




Declaration on Protection of Personal Data 
Under the laws of the Hong Kong Special Administrative Region and, in particular, the Personal Data 
(Privacy) Ordinance, Cap 486, you enjoy or may enjoy rights for the protection of the confidentiality of your 
personal data, such as those regarding the collection, custody, retention, management, control, use (including 
analysis or comparison), transfer in or out of Hong Kong, non-disclosure, erasure and/or in any way dealing with 
or disposing of any of your personal data in or for this study. 
By signing and dating this Consent Form, you agree to allow the collection, custody, retention, 
management, control, and use your personal data in this study in ways described in the Information Leaflet. For 
any query, you should consult the Privacy Commissioner for Privacy Data or his office ( Tel No. 2827 2827) as 
to the proper monitoring or supervision of your personal data protection so that your full awareness and 
understanding of the significance of compliance with the law governing privacy data is assured. 
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Consent Form  
 
The following statements are to check that you understand and consent to the procedures 
involved in taking part in this research. 
 
 
1. I confirm that I have read and understood (or had someone read and explained) the information 
for the above study and have been given a copy to keep. I have had the opportunity to ask 
questions about the project and I understand why the research is being done and any risks 
involved. 
2. I understand that my participation is voluntary. 
3. I agree to take part in the study. 
4. I agree to complete a baseline questionnaire through face-to-face interview by an interviewer at 
the clinic. 
5. I understand that I need to complete a telephone survey at 3, 6 and 12 months after the baseline 
questionnaire to monitor my progress, which will take about 10 minutes. 
6. I understand that my doctor-in-charge will manage me as usual, and provide information on my 
disease and treatment at every follow up consultations during the 12 months of the study.  
7. I understand that all information that I provide to the research team will be kept confidential and 
only the investigators and their research team will have access to it. 
8. I understand how the data will be collected, that giving data for this research is voluntary and 
that I am free to withdraw the permission to use my data at any time, without giving reason and 
without my medical treatment or legal rights being affected. 
9. I understand that I am free to withdraw from the study at any time, without giving reason and 
without my medical treatment or legal rights being affected in any way. 
10. I understand the investigators have the right to exclude me from the study in the event of inter-
current illness, adverse event, protocol violations, or other reasons. 
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Clinician Consent Form 
 
  Version No. 1 dated 2020.03.20  
 
 
A. Information and Consent Form – Clinician version 
Research conducted by 
Department of Family Medicine and Primary Care, HKU  
 
Effectiveness of Routine Measurement of Health-Related Quality of Life in Improving the 
Outcomes of Patients with Musculoskeletal Problems – A Randomized Controlled Trial 
 
Thank you for reading this information and agreeing to consider taking part in this study. Please read 
this form, and if you have understood the purpose and procedure of the study and kindly agree 
to take part, please sign and date at the end of this Consent Form. 
 
Study Information 
The aim of this research is to determine the effectiveness of routine measurement of health-
related quality of life (HRQOL) in improving the clinical outcomes of patients with chronic knee or back 
problems in primary care. You will be invited to report on the health of the patients you see. During 
the study period (12 months), you will be asked to rate on the disease severity and progression of the 
patients whenever you see them.   
 
Your clinic will be RANDOMLY assigned to one of the two study arms: (1) Intervention group: 
subjects will complete the electronic EQ-5D-5L and be given a report on their HRQOL to you during 
the consultation and you will manage the patients based on the HRQOL and clinical information; (2) 
Control group: subjects will not complete the electronic EQ-5D-5L and you will manage the patients 
as usual..  
 
All the data collected from you will be kept confidential and no individual identity information 
will be disclosed in any reports, data record forms or publications. 
 
For further information please contact: 
Prof. Cindy Lam or Dr. Carlos Wong 
Department of Family Medicine and Primary 
Care, The University of Hong Kong 
3/F., Ap Lei Chau Clinic, 161 Main Street, Ap Lei Chau, Hong Kong 
Telephone: 2518 5657; Fax: 2814 7475 
 
Declaration on Protection of Personal Data 
Under the laws of the Hong Kong Special Administrative Region and, in particular, the Personal 
Data (Privacy) Ordinance, Cap 486, you enjoy or may enjoy rights for the protection of the 
confidentiality of your personal data, such as those regarding the collection, custody, retention, 
management, control, use (including analysis or comparison), transfer in or out of Hong Kong, non-
disclosure, erasure and/or in any way dealing with or disposing of any of your personal data in or for 
this study. 
By signing and dating this Consent Form, you agree to allow the collection, custody, retention, 
management, control, and use your personal data in this study in ways described in the Information 
Leaflet. For any query, you should consult the Privacy Commissioner for Privacy Data or his office ( 
Tel No. 2827 2827) as to the proper monitoring or supervision of your personal data protection so that 
your full awareness and understanding of the significance of compliance with the law governing 
privacy data is assured. 
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Clinician Consent Form  
  Version No. 1 dated 2020.03.20  
A. Information and Consent Form – Clinician 
version 
 
The following statements are to check that you understand and consent to the 
procedures involved in taking part in this research. 
 
 
1. I confirm that I have read and understood (or had someone read and explained) 
the information for the above study and have been given a copy to keep. I have 
had the opportunity to ask questions about the project and I understand why the 
research is being done and any risks involved. 
2. I understand that my participation is voluntary. 
3. I agree to take part in the study. 
4. I agree to complete a questionnaire rating on the patients’ disease severity and 
progression very time I see him/her during the study period. 
5. I understand that my clinic will be randomly assigned EITHER TO THE 
INTERVENTION OR CONTROL GRPOUP, that I need to manage the 
patients based on HRQOL and clinical information or solely on the clinical 
information depending on the my clinic group allocation  
6. I understand that all information that I provide to the research team will be kept 
confidential and only the investigators and their research team will have access 
to it. 
7. I understand how the data will be collected, that giving data for this research is 
voluntary. 
8. I understand that I am free to withdraw from the study at any time, without giving 
reason and without my legal rights being affected in any way. 
9. I understand the investigators have the right to exclude me from the study in the 











…………………………………………          ………………………………………  …………………………..  






…………………………………………          …………………………………………   ……………………..  
Name of Investigator in                                            Signature               Date 
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Effectiveness of Routine Measurement of Health-Related Quality of Life in 
Improving the Outcomes of Patients with Musculoskeletal Problems – A 






Number：   
 







Part 1. Morbidity data 
 
Part 2. Health service utilization 
 
Part 3. Socio-demographics and lifestyle factors 
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Part 1. Morbidity data 
 
 
Diagnosis – what is the type of your musculoskeletal disorders diagnosed by a western doctor? 
Musculoskeletal disorder diagnosis: ① Knee          ② Back ③others __________________  
Diagnosis year:  If don’t know⓪<1 year ① 1-5 years ② 5- 10 years ③> 10 years 
Treatment – Have you received any treatment for musculoskeletal disorders over past three months 
Medication Topical ⓪ No ① Yes, please specify: How many  , Frequency:  times/day 
Oral ⓪ No ① Yes, please specify: How many  , Frequency:  times/day  
             Injection       ⓪ No ① Yes, please specify: How many  , Frequency:  times/day 
Physiotherapy ⓪ No ① Yes If yes, frequency:  times/week 
Occupational therapy ⓪ No ① Yes   If yes, frequency:  times/week 
Local injection        ⓪ No ① Yes   If yes, frequency:  times/week 
Surgery ⓪ No ① Yes    If yes, type:  ; Surgery year:    
Counselling ⓪ No ① Yes If yes, frequency:  times 
 Co-morbidities – Do you have any of the following disease diagnosed by a western doctor? 
 
 
Hypertension ⓪ No ① Yes Diabetes ⓪ No ① Yes 
Stroke (or Transient 
Ischaemic Attack) 
⓪ No ① Yes Heart disease ⓪ No ① Yes 
Pulmonary diseases (asthma 
and COPD ) 
⓪ No ① Yes Mental health disease 
(depression/anxiety) 
⓪ No ① Yes 
Renal Disease ⓪ No    ① Yes Osteoporosis ⓪ No ① Yes 
Cancer 
⓪ No    ① Yes 
Others 
⓪ No ① Yes , 
please specify    
Sick leave 
During last month, have you taken any sick leave? 
 
a) For musculoskeletal disorders 
 
b) For other reasons? 
⓪ No ① Yes ⓪ No ① Yes ,  How many days?    
 
    ⓪ No ① Yes ,  How many  days ?    
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Part 2. Health service utilization 
1. During past one month, have you ever consulted Western 
medicine practitioners? 
a) For musculoskeletal disorders 
b) For other reasons? 
 ⓪ No 
 ⓪ No ⓪ No 
 ① Yes 
 ① Yes, How many times?    ① Yes, How many times?    
2. During past one month, have you ever consulted Chinese 
medicine practitioners? 
a) For musculoskeletal disorders 
b) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes 
 ① Yes, How many times?    ① Yes, How many times?    
3.  During past one month, have you ever self-medicated? 
 
c) For musculoskeletal disorders 
d) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes 
 ① Yes, How many times?    ① Yes, How many times?    
4.  During past one month, have you ever visited the emergency 
room? 
a) For musculoskeletal disorders 
b) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes , 
 ① Yes, How many times?    ① Yes, How many times?    
5.  During past one month, have you ever visited the allied health 
service? 
c) For musculoskeletal disorders 
d) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes , 
 ① Yes, How many times?    ① Yes, How many times?    
6.  During past three months, have you ever attended and stayed 
more one or more nights in hospital? 
a) For musculoskeletal disorders 
b) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes , 
 ① Yes, How many nights?    ① Yes, How many nights ? _____ 
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Part 3: Socio-demographics and lifestyle factors 
 
  
Age:   Date of birth (DD/MM/YYYY)：   
 
Sex: ⓪Female  ①Male / /__________ 
Education       ⓪None   
               ①Primary or below 
               ②Secondary Level 
          ③Tertiary level or above 
 
Occupation: ⓪Unemployed  
               ① Home-maker  
               ②Retired  
                ③ Manual 
                ④Clerical  
                ⑤Professional or managerial 
                 ⑥ Other：________________________________________   
 
 Marital status ⓪Never married  ①Married ②Separated ③Divorced   ④Widowed 
What is your 
average 
⓪No income  ① Less than HK$5,000 
  ②HK$5,000-9,999 ③HK$10,000-19,999  ④HK$20,000-29,999 ⑤HK$30,000-39,999 ⑥40,000 or above  ⑦ Refuse to answer ⑧ Don’t know 
monthly household 
income, including 
sources? (in HKD) 
Smoking Status: ⓪ Non-smoker ① Ex-smoker ② Current Smoker 
Drinking Habit: ⓪ Non-drinker ①Ex-drinker ② Drink 
occasionally 
 ③ Drink often 
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Effectiveness of Routine Measurement of Health-Related Quality of Life in 
Improving the Outcomes of Patients with Musculoskeletal Problems – A 
Randomized Controlled Trial 
 
 
Follow-up Assessment  
 
 
Number：   
 







Part 1. Morbidity data 
 
Part 2. Health service utilization 
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  Part 1. Morbidity data 
 
 
Disease diagnosis – what is the type of your musculoskeletal disorders diagnosed by a western doctor? 
Musculoskeletal disorder diagnosis: ① Knee          ② Back ③others __________________  
Diagnosis year:  If don’t know ⓪<1 year   ① 1-5 years  ② 5- 10 years  ③> 10 years 
Treatment – Have you received any treatment for musculoskeletal disorders over past three months 
Medication Topical ⓪ No ① Yes, please specify: How many  , Frequency:  times/day 
Oral ⓪ No ① Yes, please specify: How many  , Frequency:  times/day 
Injection       ⓪ No ① Yes, please specify: How many  , Frequency:  times/day 
Home Exercise  ⓪ No ① Yes If yes, frequency:  times/week 
Physiotherapy ⓪ No ① Yes If yes, frequency:  times/week 
Occupational therapy  ⓪ No  ① Yes   If yes, frequency:  times/week 
Local injection        ⓪ No ① Yes If yes, frequency:  times/week 
Surgery ⓪ No ① Yes    If yes, type:  ; Surgery year:    
Counselling ⓪ No ① Yes If yes, frequency:  times 
Co-morbidities – Do you have any of the following disease diagnosed by a western doctor? 
 
 
Hypertension ⓪ No ① Yes Diabetes ⓪ No ① Yes 
Stroke (or Transient 
Ischaemic Attack) 
⓪ No ① Yes Heart disease ⓪ No ① Yes 
Pulmonary diseases (asthma 
and COPD ) 
⓪ No ① Yes Mental health disease 
(depression/anxiety) 
⓪ No ① Yes 
Renal Disease ⓪ No    ① Yes Osteoporosis ⓪ No ① Yes 
Cancer 
⓪ No    ① Yes 
Others 
⓪ No ① Yes , 
please specify    
Sick leave 
During the past one month, have you taken any sick leave? 
 
a) For  musculoskeletal disorders 
 
b) For other reasons? 
⓪ No ① Yes ⓪ No ① Yes ,  How many days?    
    ⓪ No ① Yes ,  How many  days ?    
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Part 2. Health service utilization 
 
 
1. During past one month, have you ever consulted Western 
medicine practitioners? 
c) For  musculoskeletal disorders 
d) For other reasons? 
 ⓪ No 
 ⓪ No ⓪ No 
 ① Yes 
 ① Yes, How many times?    ① Yes, How many times?    
2.    During past one month, have you ever consulted Chinese 
medicine practitioners? 
e) For  musculoskeletal disorders 
f) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes 
 ① Yes, How many times?    ① Yes, How many times?    
3.  During past one month, have you ever self-medicated? 
 
g) For  musculoskeletal disorders 
h) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes 
 ① Yes, How many times?    ① Yes, How many times?    
4.  During past one month, have you ever visited the emergency 
room? 
c) For  musculoskeletal disorders 
d) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes , 
 ① Yes, How many times?    ① Yes, How many times?    
5.  During past one month, have you ever visited the allied health 
service? 
e) For  musculoskeletal disorders 
f) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes , 
 ① Yes, How many times?    ① Yes, How many times?    
6.  During past three months, have you ever attended and stayed 
more one or more nights in hospital? 
c) For  musculoskeletal disorders 
d) For other reasons? 
⓪ No 
 ⓪ No ⓪ No 
① Yes , 
 ① Yes, How many nights?  
  ① Yes, How many nights ?  
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號碼：   
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確診年份:    
 
               如忘記年份:      ⓪少於一年 ① 一至五年 ② 五至十年 ③
超過十年
治療措施:   在過去3 個月，您是否因筋骨健康問題而接受治療？ 
藥物治療 藥膏      ⓪ 沒有 ① 有，請註明數量:  天, 次數:  次/天 
口服藥  ⓪ 沒有 ① 有，請註明數量:  天, 次數:  次/天 
                  注射用藥  ⓪ 沒有           ① 有，請註明數量:  _________, 次 
物理治療    ⓪ 沒有 ① 有 如有, 次數:  次/周 
職素治療    ⓪ 沒有 ① 有 如有, 次數:  次/周 
局部注射 ⓪ 沒有 ① 有 如有, 次數:  次/周 
手術 ⓪ 沒有 ① 有 如有, 種類:  ; 手術年份:    
心理輔導 ⓪ 沒有 ① 有 如有, 次數:  次 
慢性疾病:   您是否被西醫診斷患有以下任何一種疾病？ 
心臟病 ⓪ 沒有 ① 有 高血壓 ⓪ 沒有 ① 有 
中風(或短暫性腦缺血) ⓪ 沒有 ① 有 糖尿病 ⓪ 沒有 ① 有 
肺病（哮喘或慢性阻塞性 
肺病） ⓪ 沒有 ① 有 精神疾病（抑鬱症或焦慮 
症） 
⓪ 沒有 ① 有 
腎病 ⓪ 沒有 ① 有 關節炎 ⓪ 沒有 ①有 
癌症 
⓪ 沒有 ① 有, 
請註明:   
其他疾病 
 ⓪ 沒有   ① 有, 





⓪ 沒有 ① 有,   天數： ______  
⓪ 沒有  ① 有 , 天數： ____  
⓪ 沒有 ① 有 , 天數： ____  
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次數：    
次數：    














次數：    
次數：    











次數：    
次數：    













次數：    
次數：    













次數：    
次數：    









 天數: _____   
天數：    
天數：    
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第三部分 - 背景和生活習慣 
 
年齡：   出生日期 (日/月/年)：  / /  
 
性別： ⓪女 ①男 
教育程度： ⓪沒有接受教育 ①小學程度 ②中學程度 ③高等程度或以上 
職業： ⓪沒有工作 ①家庭主理者 ②已退休 
 ④文職 ⑤專業或管理人士 ③勞動工作  ⑥ 其他：   
婚姻狀況： ⓪從未結婚 ①已婚 ②分居 ③離婚 ④喪偶 
您的平均家庭月收 ⓪沒有收入 ① 少於 HK$5,000 ②HK$5,000-9,999 
入有多少？（包括 ③HK$4,000-5,999 ④HK$6,000-7,999 ⑤HK$8,000-9,999 
所有經濟來源）(港 
幣) 
⑥40,000 以上 ⑦ 拒絕作答 ⑧ 不清楚 
吸煙習慣: ⓪不吸煙者 ①戒煙者 ②吸煙者 
飲酒習慣： ⓪沒有飲酒習慣 ①戒酒者 ②偶爾飲酒 ③經常飲酒 
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號碼：   
 










BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open




Appendix 3 – Structured Questionnaire  









確診年份:    
 
               如忘記年份:      ⓪少於一年 ① 一至五年 ② 五至十年 ③
超過十年
治療措施:   在過去3個月，您是否因筋骨健康問題而接受治療？ 
藥物治療 藥膏      ⓪ 沒有 ① 有，請註明數量:  天, 次數:  次/天 
口服藥  ⓪ 沒有 ① 有，請註明數量:  天, 次數:  次/天 
                  注射用藥  ⓪ 沒有           ① 有，請註明數量:  _________ 次 
物理治療    ⓪ 沒有 ① 有 如有, 次數:  次 
職素治療    ⓪ 沒有 ① 有 如有, 次數: _______次 
局部注射 ⓪ 沒有 ① 有 如有, 次數:   
手術 ⓪ 沒有 ① 有 如有, 種類:  ; 手術年份:    
心理輔導 ⓪ 沒有 ① 有 如有, 次數:  次 
慢性疾病:   您是否被西醫診斷患有以下任何一種疾病？ 
心臟病 ⓪ 沒有 ① 有 高血壓 ⓪ 沒有 ① 有 
中風(或短暫性腦缺血) ⓪ 沒有 ① 有 糖尿病 ⓪ 沒有 ① 有 
肺病（哮喘或慢性阻塞性 
肺病） ⓪ 沒有 ① 有 精神疾病（抑鬱症或焦慮 
症） 
⓪ 沒有 ① 有 
腎病 ⓪ 沒有 ① 有 關節炎 ⓪ 沒有  ① 有 
癌症 
⓪ 沒有 ① 有, 
 
請註明:   
其他疾病 
 ⓪ 沒有    ① 有, 
 





⓪ 沒有 ① 有,   天數： ______  
⓪ 沒有  ① 有 , 天數： ____  
⓪ 沒有 ① 有 , 天數： ____  
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天數：    
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Effectiveness of Routine Measurement of Health-Related Quality of Life in 
Improving the Outcomes of Patients with Musculoskeletal Problems – A 







Number：   
 
Date (DD/MM/YYYY)：   
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Global Rating on Disease Severity 
 
How would you rate the patient’s disease severity today? 








Disease diagnosis – 
What is the patient’s main musculoskeletal diagnosis (can choose one or more)?   
 ⓪  Knee, diagnosis ________________   ① Back, diagnosis ________________ ② Others: ___________________   
 
Diagnosis year:   __   If don’t know:  ⓪ <1 year  ① 1-5 years  ② 5- 10 years ③> 10 years 
Management – 
Have you advised any of the following management for the patient’s musculoskeletal disorders today? 
 
Investigations  ⓪ No   ① Yes, (circle):   X ray    CT     MRI     Others: ________________________ 
 
Topical  ⓪ No   ① Yes (circle):  analgesic balm    Others _____________   
Oral          ⓪ No   ① Yes, (circle):  paracetamol  NSAID  others, ____________________________________ 
Injection      ⓪ No   ① Yes, (circle):  NSAID   opioid   others, :   
 Home-care    ⓪ No  ① Yes (circle)  Ice pack   Heat pad    brace/splint   home exercise  others_________     
Others:__________ 
Physiotherapy ⓪ No  ① Yes   please specify ____________________________   
Occupational Therapy   ⓪ No  ① Yes   please specify ____________________________   
Prosthesis & Orthosis   ⓪ No   ① Yes,  please specify ____________________________   
Local injection ⓪ No   ① Yes, please specify frequency: ________________ times 
Referral ⓪ No   ① Yes (circle): Orthopedics,  Surgery  Chiropractor  Others ______________  
Others ⓪ No   ① Yes  please specify:__________________________________________ 
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Improving the Outcomes of Patients with Musculoskeletal Problems – A 






Number：   
 
Date (DD/MM/YYYY)：  ________ 
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Appendix 4: Clinician Report Form (CRF) 
 
Clinical data 
Global Rating on Disease Severity 
 
How would you rate the patient’s severity of the patient’s musculoskeletal problem today? 
 ⓪ No problem   ① Mild    ② Moderate    ③ Severe   ④ Very severe  
 
Global Rating on Disease Progression 
 
Compare to the patient’s condition on              (date of recruitment visit), 
how would you rate the patient’s musculoskeletal problem today? 
 
Much Worse A little No changed A little Better Much better 
worse  worse  better   
+3 -2 -1 0 +1 +2 +3
Disease diagnosis – 
What is the patient’s main musculoskeletal diagnosis (can choose one or more)?   
 ⓪  Knee, diagnosis ________________   ① Back, diagnosis ________________ ② Others: ___________________   
 
Diagnosis year:   __   If don’t know:  ⓪ <1 year  ① 1-5 years  ② 5- 10 years ③> 10 years 
Management – 
Have you advised any of the following management for the patient’s musculoskeletal disorders today? 
 
Investigations  ⓪ No   ① Yes, (circle):   X ray    CT     MRI     Others: ________________________ 
 
Topical  ⓪ No   ① Yes (circle):  analgesic balm    Others _____________   
Oral          ⓪ No   ① Yes, (circle):  paracetamol  NSAID  others, ____________________________________ 
Injection      ⓪ No   ① Yes, (circle):  NSAID   opioid   others, :   
 Home-care    ⓪ No  ① Yes (circle)  Ice pack   Heat pad    brace/splint   home exercise  others_________     
Others:__________ 
Physiotherapy ⓪ No  ① Yes   please specify ____________________________   
Occupational Therapy   ⓪ No  ① Yes   please specify ____________________________   
Prosthesis & Orthosis   ⓪ No   ① Yes,  please specify ____________________________   
Local injection ⓪ No   ① Yes, please specify frequency: ________________ times 
Referral ⓪ No   ① Yes (circle): Orthopedics,  Surgery  Chiropractor  Others ______________  
Others ⓪ No   ① Yes  please specify:__________________________________________ 
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Perceived usefulness of the EQ-5D-5L report (for intervention group only) 
 (Please ✓ the appropriate answer for each question)  













1. The EQ-5D data report is 
clear 
       
2. The EQ-5D data report is 
easy to understand 
       
3. The EQ-5D data report helps 
me to understand the 
patient’s needs better  
       
4. Using the EQ-5D-5L data 
report helps the management 
for my patient 
       
5.  I wish to have the EQ-5D 
data report of the patient 
available to me in future 
consultations 
       
6. Apart from the domains included in the EQ-5D, is there any other aspect of the patient’s quality of life 
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Appendix 5: Summary of RCT Plan by CONSORT Criteria 
CONSORT Criteria Study Plan  
Participants allocation Random 
Rationale HRQOL data optimize care to address physical, psychological and social needs, resulting in 
improvement in quality of life & daily function 
Eligibility criteria and 
settings  
Adults with chronic MS problems diagnosed by the doctor in study outpatient clinics 
Interventions for each group  EQ-5D-5L report to the doctor plus usual care Vs. usual care only 
Objectives Effectiveness of routine measurement of EQ-5D-5L by an electronic platform in improving 
HRQOL and pain control in patients with chronic MS problems 
 
Feasibility of routine measurement of EQ-5D-5L by an electronic platform in busy outpatient 
clinics 
Outcomes Changes in WAOMAC, pain, SF-6D, clinician rated disease severity, same for both groups 
Sample size 543 from primary and specialist orthopedic outpatient clinics to detect an effect size of 0.3 in 
WOMAC score between groups, allowing 30% attrition. 
Randomization -- 
Sequence generation 
Post recruitment 1:1 block randomization 
Randomization -- 
Allocation concealment 
Computer generated random number table for each site, concealed to research assistant at 
recruitment and follow-up assessors. 
Randomization -- 
Implementation 
Independent statistician generates the allocation sequence randomly by computer  and group 
allocation by statistician according to computer generated random number sequence 
Blinding (masking)  Assessor is blinded 
Statistical methods  Descriptive statistics,  Paired T tests, ANCOVA, multiple logistic regression 
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